March 2, 2009. Just published in the Journal of Clinical Investigation.1 And we even got the cover. Twists and turns of heat shock protein-90 (Hsp90), the chaperone, the evolutionary capacitor. Great name and important cancer target. People smiled when I talked about this at the Hsp90 conference....
Five years ago, the Helen F. Graham Cancer Center and Research Institute at Christiana Care Health System in Newark, Delaware, and The Wistar Institute, a National Cancer Institute (NCI)-designated biomedical research center, in Philadelphia, Pennsylvania, joined forces to collaborate on...
The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only ...